Aminur Khan, MD
Gastroenterology · Baltimore, MDNPI 1114009263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,875 of the $118,197 with a category attached, or 87.9%. AbbVie accounts for 92.0% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $35,821 and has fallen 93.9% since, to $2,172 in 2025. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 868 payments — averaging $136.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$109K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$780
- Regeneron Healthcare Solutions, Inc.$749
- Bristol Myers Squibb$614
- plus $4K from 31 others
What the payments were for
- Consulting fees$180%
- Speaking & faculty fees$103,87588%
- Food & beverage$14,16812%
- Education$730%
- Gifts$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,197 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 167 | $149,512 |
| ZenpepLipase/Protease/Amylase | 20 | $84,012 |
| Humira PenAdalimumab | 12 | $81,738 |
| CreonLipase/Protease/Amylase | 12 | $35,496 |
| Mesalamine | 64 | $32,472 |
| XifaxanRifaximin | 22 | $28,070 |
| PentasaMesalamine | 13 | $27,640 |
| Pantoprazole Sodium | 1,171 | $18,803 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 142 | $16,584 |
| CholestyramineCholestyramine (With Sugar) | 150 | $15,111 |
| Dexlansoprazole DrDexlansoprazole | 40 | $14,392 |
| Famotidine | 820 | $12,395 |
| TrulancePlecanatide | 17 | $11,016 |
| Sucralfate | 139 | $9,392 |
| Mesalamine ErMesalamine | 31 | $9,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $108,794 | $185,007179 claims |
| Aimmune Therapeutics, Inc.Zenpep | $88 | $84,01220 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $780 | $39,08639 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $168 | $20,022164 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $1,102 | $8,83112 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $233 | $6,22537 claims |
| Redhill Biopharma Inc.Movantik | $55 | $5,31113 claims |
| SandozLansoprazole | $30 | $48615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Baltimore
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Raymond CrossBaltimore$341K
- Paul ThuluvathBaltimore$231K
- Niraj JaniBaltimore$214K
- Eric GoldbergBaltimore$110K
- Saowanee NgamruengphongBaltimore$90K
- Venkata AkshintalaBaltimore$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.